Clinical Trials Logo
  1. Home
  2. Non-Small Cell Lung Cancer
  3. NCT05537701
  4. Details
NCT05537701 Clinical Trial

Tissue Eosinophils in Non-Small Cell Lung Cancer (the TEN Study)

Non-small Cell Lung Cancer Clinical Trial

— TEN  

Official title:
Tissue Eosinophils in Non-Small Cell Lung Cancer (the TEN Study)

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT05537701
Other study ID # 2022/158
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 3, 2022
Est. completion date March 31, 2027

Study information
Verified date January 2024
Source Centre Hospitalier Universitaire de Liege
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The primary objective is to describe eosinophil infiltration in resected (early stage) NSCLC. Secondary objectives are: - to investigate the correlation of T-Eos and B-Eos in the aforementioned patient population; - to investigate the correlation between T-Eos and overall & disease-free survival; - to investigate the localization of T-Eos (periphery vs. center of the tumor lesions).

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 316
Est. completion date March 31, 2027
Est. primary completion date March 31, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Resected, early stage NSCLC between 01-01-2015 and 30-04-2022 with available tumour tissue Exclusion Criteria: - Inclusion in a clinical study contraindicating enrollment in the present study

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Belgium CHU de Liege Liège

Sponsors (1)
Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Liege

Country where clinical trial is conducted

Belgium, 

Outcome
Type Measure Description Time frame Safety issue
Primary Percentage of tumor associated tissue eosinophilia by immunohistochemistry and computerised quantification October 2022
Secondary to investigate the correlation of tissue (T)-Eos and blood (B)-Eos in the aforementioned patient population Tissue and blood eosinophil correlation December 2022
Secondary to investigate the correlation between T-Eos and overall & disease-free survival overall and disease-free survival December 2022
Secondary to investigate the localization of T-Eos (periphery vs. center of the tumor lesions) tissue eosinophil localisation December 2022
See also
  Status Clinical Trial Phase
Terminated NCT03087448 - Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Phase 1
Recruiting NCT05042375 - A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Phase 3
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Terminated NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Recruiting NCT05009836 - Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03219970 - Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
Recruiting NCT05949619 - A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors Phase 1/Phase 2
Recruiting NCT04054531 - Study of KN046 With Chemotherapy in First Line Advanced NSCLC Phase 2
Withdrawn NCT03519958 - Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Terminated NCT02580708 - Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer Phase 1/Phase 2
Completed NCT01871805 - A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Recruiting NCT05919641 - LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
Completed NCT03656705 - CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma Phase 1